Close

UBS on Healthcare Distribution - PBMs: Implications from SXCI/CHSI Deal

April 19, 2012 1:37 PM EDT
Get Alerts CVS Hot Sheet
Price: $79.66 +0.29%

Rating Summary:
    27 Buy, 11 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 10 | New: 11
Join SI Premium – FREE
UBS on Healthcare Distribution - PBMs: Implications from SXCI/CHSI Deal

Analyst, Steven Valiquette, said, "The timing of the newly proposed PBM merger between SXCI and CHSI has occurred a bit earlier than most investors were expecting, and thus raised some questions as to whether the deal is offensive or defensive in nature."

"While the combined SXCI/CHSI entity will obviously have greater scale than either company on a standalone basis, we do not see the combined company with only 5.8% market share suddenly being large enough to be a material threat to the growth trajectory of either ESRX/MHS or CVS. Thus, we make no changes to our ESRX and CVS estimates in light of this transaction. We also believe that this transaction has no bearing on whether WAG/ESRX will settle their payor dispute."

UBS maintains a 'Buy' on CVS (NYSE: CVS) and Express Scripts (Nasdaq: ESRX). Maintains a 'Neutral' on SXC Health Solutions (Nasdaq: SXCI), but raises price target from $64 to $90. Other stocks of note: Catalyst Health Solutions (Nasdaq: CHSI) and Medco (NYSE: MHS).


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Mergers and Acquisitions

Related Entities

UBS